Abstract
The aim of this study was to establish the physiologically based pharmacokinetic (PBPK) model of flurbiprofen related to CYP2C9 genetic polymorphism and describe the pharmacokinetics of flurbiprofen in different CYP2C9 genotypes. PK-Sim® software was used for the model development and validation. A total of 16 clinical pharmacokinetic data for flurbiprofen in different CYP2C9 genotypes, dose regimens, and age groups were used for the PBPK modeling. Turnover number (kcat) of CYP2C9 values were optimized to capture the observed profiles in different CYP2C9 genotypes. In the simulation, predicted fraction metabolized by CYP2C9, fraction excreted to urine, bioavailability, and volume of distribution were similar to previously reported values. Predicted plasma concentration-time profiles in different CYP2C9 genotypes were visually similar to the observed profiles. Predicted AUCinf in CYP2C9*1/*2, CYP2C9*1/*3, and CYP2C9*3/*3 genotypes were 1.44-, 2.05-, and 3.67-fold higher than the CYP2C9*1/*1 genotype. The ranges of fold errors for AUCinf, Cmax, and t1/2 were 0.84–1.00, 0.61–1.22, and 0.74–0.94 in development and 0.59–0.98, 0.52–0.97, and 0.61–1.52 in validation, respectively, which were within the acceptance criterion. Thus, the PBPK model was successfully established and described the pharmacokinetics of flurbiprofen in different CYP2C9 genotypes, dose regimens, and age groups. The present model could guide the decision-making of tailored drug administration strategy by predicting the pharmacokinetics of flurbiprofen in various clinical scenarios.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abduljalil K, Badhan RKS (2020) Drug dosing during pregnancy-opportunities for physiologically based pharmacokinetic models. J Pharmacokinet Pharmacodyn 47(4):319–340. https://doi.org/10.1007/s10928-020-09698-w
Abouir K, Samer CF, Gloor Y, Desmeules JA, Daali Y (2021) Reviewing data integrated for PBPK model development to predict metabolic drug–drug interactions: shifting perspectives and emerging trends. Front Pharmacol 12:708299. https://doi.org/10.3389/fphar.2021.708299
Bae JW, Kim JH, Choi CI, Kim MJ, Kim HJ, Byun SA, Chang YS, Jang CG, Park YS, Lee SY (2009) Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects. Arch Pharm Res 32(2):269–273. https://doi.org/10.1007/s12272-009-1232-z
Bae JW, Choi CI, Jang CG, Lee SY (2011a) Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam. Br J Clin Pharmacol 71(4):550–555. https://doi.org/10.1111/j.1365-2125.2010.03853.x
Bae JW, Choi CI, Kim MJ, Oh DH, Keum SK, Park JI, Kim BH, Bang HK, Oh SG, Kang BS, Park HJ, Kim HD, Ha JH, Shin HJ, Kim YH, Na HS, Chung MW, Jang CG, Lee SY (2011b) Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics. Acta Pharmacol Sin 32(10):1303–1308. https://doi.org/10.1038/aps.2011.100
Bae JW, Oh KY, Yoon SJ, Shin HB, Jung EH, Cho CK, Lim CW, Kang P, Choi CI, Jang CG, Lee SY, Lee YJ (2020) Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide. Arch Pharm Res 43(11):1207–1213. https://doi.org/10.1007/s12272-020-01293-4
Buchanan WW, Kassam YB (1986) European experience with flurbiprofen: a new analgesic/anti-inflammatory agent. Am J Med 80(3):145–152. https://doi.org/10.1016/0002-9343(86)90134-8
Byeon JY, Kim YH, Na HS, Jang JH, Kim SH, Lee YJ, Bae JW, Kim IS, Jang CG, Chung MW, Lee SY (2015) Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites. Arch Pharm Res 38(11):2083–2091. https://doi.org/10.1007/s12272-015-0646-z
Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY (2021a) Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele. Arch Pharm Res 44(11):1037–1049. https://doi.org/10.1007/s12272-021-01357-z
Cho CK, Park HJ, Kang P, Moon S, Lee YJ, Bae JW, Jang CG, Lee SY (2021b) Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes. Arch Pharm Res 44(12):1076–1090. https://doi.org/10.1007/s12272-021-01361-3
Choi CI, Kim MJ, Jang CG, Park YS, Bae JW, Lee SY (2011) Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam. Basic Clin Pharmacol Toxicol 109(6):476–480. https://doi.org/10.1111/j.1742-7843.2011.00751.x
Choi CI, Kim MJ, Chung EK, Lee HI, Jang CG, Bae JW, Lee SY (2012) CYP2C9*3 and *13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects. Eur J Clin Pharmacol 68(2):149–154. https://doi.org/10.1007/s00228-011-1098-0
Choi CI, Bae JW, Keum SK, Lee YJ, Lee HI, Jang CG, Lee SY (2013) Effects of OCT2 c.602 C > T genetic variant on the pharmacokinetics of lamivudine. Xenobiotica 43(7):636–640. https://doi.org/10.3109/00498254.2012.747710
Daly AK, Rettie AE, Fowler DM, Miners JO (2017) Pharmacogenomics of CYP2C9: functional and clinical considerations. J Pers Med 8(1):1. https://doi.org/10.3390/jpm8010001
Daravath B, Naveen C, Vemula SK, Tadikonda RR (2018) Solubility and dissolution enhancement of flurbiprofen by solid dispersion using hydrophilic carriers. Braz J Pharm Sci 53(4):e00010. https://doi.org/10.1590/s2175-97902017000400010
Davies NM (1995) Clinical pharmacokinetics of flurbiprofen and its enantiomers. Clin Pharmacokinet 28(2):100–114. https://doi.org/10.2165/00003088-199528020-00002
Edginton AN, Schmitt W, Willmann S (2006) Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet 45(10):1013–1034. https://doi.org/10.2165/00003088-200645100-00005
El-Khateeb E, Burkhill S, Murby S, Amirat H, Rostami-Hodjegan A, Ahmad A (2021) Physiological-based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20-years; in-depth analysis of applications, organizations, and platforms. Biopharm Drug Dispos 42(4):107–117. https://doi.org/10.1002/bdd.2257
Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286(5439):487–491. https://doi.org/10.1126/science.286.5439.487
Ferreira A, Lapa R, Vale N (2021) PBPK modeling and simulation and therapeutic drug monitoring: possible ways for antibiotic dose adjustment. Processes 9(11):2087. https://doi.org/10.3390/pr9112087
Hanley MJ, Masse G, Harmatz JS, Court MH, Greenblatt DJ (2012) Pomegranate juice and pomegranate extract do not impair oral clearance of flurbiprofen in human volunteers: divergence from in vitro results. Clin Pharmacol Ther 92(5):651–657. https://doi.org/10.1038/clpt.2012.170
Heimbach T, Chen Y, Chen J, Dixit V, Parrott N, Peters SA, Poggesi I, Sharma P, Snoeys J, Shebley M, Tai G, Tse S, Upreti VV, Wang YH, Tsai A, Xia B, Zheng M, Zhu AZX, Hall S (2021) Physiologically-based pharmacokinetic modeling in renal and hepatic impairment populations: a pharmaceutical industry perspective. Clin Pharmacol Ther 110(2):297–310. https://doi.org/10.1002/cpt.2125
Hindmarsh AC, Reynolds DR, Serban R, Woodward CS, Gardner DJ, Cohen SD, Taylor A, Peles S, Banks L, Shumaker D (2021) Open systems pharmacology suite manual version 10. Available from https://docs.open-systems-pharmacology.org/. Accessed 23 May 2022
Jung EH, Lee CM, Byeon JY, Shin HB, Oh KY, Cho CK, Lim CW, Jang CG, Lee SY, Lee YJ (2020a) Relationship between plasma exposure of zolpidem and CYP2D6 genotype in healthy Korean subjects. Arch Pharm Res 43(9):976–981. https://doi.org/10.1007/s12272-020-01250-1
Jung EH, Lee YJ, Kim DH, Kang P, Lim CW, Cho CK, Jang CG, Lee SY, Bae JW (2020b) Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes. Arch Pharm Res 43(12):1356–1363. https://doi.org/10.1007/s12272-020-01300-8
Jung EH, Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Choi CI, Jang CG, Lee SY (2021) Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients. Arch Pharm Res 44(12):1109–1119. https://doi.org/10.1007/s12272-021-01363-1
Kean WF, Antal EJ, Grace EM, Cauvier H, Rischke J, Buchanan WW (1992) The pharmacokinetics of flurbiprofen in younger and elderly patients with rheumatoid arthritis. J Clin Pharmacol 32(1):41–48. https://doi.org/10.1002/j.1552-4604.1992.tb03786.x
Kim SH, Kim DH, Byeon JY, Kim YH, Kim DH, Lim HJ, Lee CM, Whang SS, Choi CI, Bae JW, Lee YJ, Jang CG, Lee SY (2017) Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite. Arch Pharm Res 40(3):382–390. https://doi.org/10.1007/s12272-016-0861-2
Kim YH, Kang P, Cho CK, Jung EH, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY (2021) Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism. Arch Pharm Res 44(7):713–724. https://doi.org/10.1007/s12272-021-01346-2
Kim NT, Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY (2022) Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects. Arch Pharm Res 45(2):114–121. https://doi.org/10.1007/s12272-021-01366-y
Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D (2016) Applied concepts in PBPK modeling: how to build a PBPK/PD model. CPT Pharmacometrics Syst Pharmacol 5(10):516–531. https://doi.org/10.1002/psp4.12134
Kumar V, Brundage RC, Oetting WS, Leppik IE, Tracy TS (2008) Differential genotype dependent inhibition of CYP2C9 in humans. Drug Metab Dispos 36(7):1242–1248. https://doi.org/10.1124/dmd.108.020396
Kumpulainen E, Välitalo P, Kokki M, Lehtonen M, Hooker A, Ranta VP, Kokki H (2010) Plasma and cerebrospinal fluid pharmacokinetics of flurbiprofen in children. Br J Clin Pharmacol 70(4):557–566. https://doi.org/10.1111/j.1365-2125.2010.03720.x
Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA (2003) Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. Eur J Clin Pharmacol 58(12):791–794. https://doi.org/10.1007/s00228-003-0574-6
Lee HI, Bae JW, Choi CI, Lee YJ, Byeon JY, Jang CG, Lee SY (2014) Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals. Pharmacogenet Genomics 24(2):113–117. https://doi.org/10.1097/fpc.0000000000000025
Lee YJ, Byeon JY, Kim YH, Kim SH, Choi CI, Bae JW, Sohn UD, Jang CG, Lee J, Lee SY (2015) Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects. Arch Pharm Res 38(6):1232–1237. https://doi.org/10.1007/s12272-015-0580-0
Lee J, Yang Y, Zhang X, Fan J, Grimstein M, Zhu H, Wang Y (2021) Usage of in vitro metabolism data for drug–drug interaction in physiologically based pharmacokinetic analysis submissions to the US Food and Drug Administration. J Clin Pharmacol 61(6):782–788. https://doi.org/10.1002/jcph.1819
Liu YM, Liu GY, Liu Y, Li SJ, Jia JY, Zhang MQ, Lu C, Zhang YM, Li XN, Yu C (2009) Pharmacokinetic and bioequivalence comparison between orally disintegrating and conventional tablet formulations of flurbiprofen: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy chinese male volunteers. Clin Ther 31(8):1787–1795. https://doi.org/10.1016/j.clinthera.2009.08.008
Loisios-Konstantinidis I, Cristofoletti R, Jamei M, Turner D, Dressman J (2020) Physiologically based pharmacokinetic/pharmacodynamic modeling to predict the impact of CYP2C9 genetic polymorphisms, co-medication and formulation on the pharmacokinetics and pharmacodynamics of flurbiprofen. Pharmaceutics 12(11):1049. https://doi.org/10.3390/pharmaceutics12111049
Mano Y, Usui T, Kamimura H (2007) Predominant contribution of UDP-glucuronosyltransferase 2B7 in the glucuronidation of racemic flurbiprofen in the human liver. Drug Metab Dispos 35(7):1182–1187. https://doi.org/10.1124/dmd.107.015347
Marok FZ, Fuhr LM, Hanke N, Selzer D, Lehr T (2021) Physiologically based pharmacokinetic modeling of bupropion and its metabolites in a CYP2B6 drug–drug–gene interaction network. Pharmaceutics. https://doi.org/10.3390/pharmaceutics13030331
Nishimura M, Naito S (2005) Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet 20(6):452–477. https://doi.org/10.2133/dmpk.20.452
Nishimura M, Naito S (2006) Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet 21(5):357–374. https://doi.org/10.2133/dmpk.21.357
Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T (2003) Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 123(5):369–375. https://doi.org/10.1248/yakushi.123.369
Patel B, Jackson S, Swift C, Hutt A (2003) Disposition of flurbiprofen in man: influence of stereochemistry and age. Xenobiotica 33(10):1043–1057. https://doi.org/10.1080/00498250310001602739
Perini JA, Vianna-Jorge R, Brogliato AR, Suarez‐Kurtz G (2005) Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. Clin Pharmacol Ther 78(4):362–369. https://doi.org/10.1016/j.clpt.2005.06.014
Pfizer (2016) ANSAID® (flurbiprofen) prescribing information. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018766s020lbl.pdf. Accessed 23 May 2022
Plowchalk DR, Rowland Yeo K (2012) Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. Eur J Clin Pharmacol 68(6):951–960. https://doi.org/10.1007/s00228-011-1189-y
Qayyum A, Najmi MH, Abbas M (2013) Comparative bioavailability and pharmacokinetics of two oral formulations of flurbiprofen: a single-dose, randomized, open-label, two-period, crossover study in Pakistani subjects. Pak J Pharm Sci 26(6):1221–1227
Rettie AE, Jones JP (2005) Clinical and toxicological relevance of CYP2C9: drug–drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol 45:477–494. https://doi.org/10.1146/annurev.pharmtox.45.120403.095821
Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping—attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57(5):465–480. https://doi.org/10.1016/s0006-2952(98)00268-8
Rüdesheim S, Wojtyniak JG, Selzer D, Hanke N, Mahfoud F, Schwab M, Lehr T (2020) Physiologically based pharmacokinetic modeling of metoprolol enantiomers and α-hydroxymetoprolol to describe CYP2D6 drug–gene interactions. Pharmaceutics 12(12):1200. https://doi.org/10.3390/pharmaceutics12121200
Rüdesheim S, Selzer D, Fuhr U, Schwab M, Lehr T (2022) Physiologically-based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups. CPT Pharmacometrics Syst Pharmacol 11(4):494–511. https://doi.org/10.1002/psp4.12776
Sai K, Saito Y, Maekawa K, Kim SR, Kaniwa N, Nishimaki-Mogami T, Sawada J, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Matsumura Y, Ohtsu A, Saijo N, Minami H (2010) Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemother Pharmacol 66(1):95–105. https://doi.org/10.1007/s00280-009-1138-y
Scaroni C, Mazzoni P, D’Amico E, Benvenuti C, Hind I (1984) Pharmacokinetics of oral and rectal flurbiprofen in children. Eur J Clin Pharmacol 27(3):367–369. https://doi.org/10.1007/BF00542178
Schlender JF, Meyer M, Thelen K, Krauss M, Willmann S, Eissing T, Jaehde U (2016) Development of a whole-body physiologically based pharmacokinetic approach to assess the pharmacokinetics of drugs in elderly individuals. Clin Pharmacokinet 55(12):1573–1589. https://doi.org/10.1007/s40262-016-0422-3
Schmitt W (2008) General approach for the calculation of tissue to plasma partition coefficients. Toxicol In Vitro 22(2):457–467. https://doi.org/10.1016/j.tiv.2007.09.010
Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270(1):414–423
Shin HB, Jung EH, Kang P, Lim CW, Oh KY, Cho CK, Lee YJ, Choi CI, Jang CG, Lee SY, Bae JW (2020) ABCB1 c.2677G > T/c.3435 C > T diplotype increases the early-phase oral absorption of losartan. Arch Pharm Res 43(11):1187–1196. https://doi.org/10.1007/s12272-020-01294-3
Theken KN, Lee CR, Gong L, Caudle KE, Formea CM, Gaedigk A, Klein TE, Agúndez JAG, Grosser T (2020) Clinical Pharmacogenetics Implementation Consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs. Clin Pharmacol Ther 108(2):191–200. https://doi.org/10.1002/cpt.1830
Thelen K, Coboeken K, Willmann S, Burghaus R, Dressman JB, Lippert J (2011) Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions. J Pharm Sci 100(12):5324–5345. https://doi.org/10.1002/jps.22726
Thelen K, Coboeken K, Willmann S, Dressman JB, Lippert J (2012) Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: extension to describe performance of solid dosage forms. J Pharm Sci 101(3):1267–1280. https://doi.org/10.1002/jps.22825
Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR (1996) Studies of flurbiprofen 4′-hydroxylation: additional evidence suggesting the sole involvement of cytochrome P450 2C9. Biochem Pharmacol 52(8):1305–1309. https://doi.org/10.1016/0006-2952(96)00501-1
Verscheijden LF, Koenderink JB, de Wildt SN, Russel FG (2019) Development of a physiologically-based pharmacokinetic pediatric brain model for prediction of cerebrospinal fluid drug concentrations and the influence of meningitis. PLoS Comput Biol 15(6):e1007117. https://doi.org/10.1371/journal.pcbi.1007117
Verscheijden LFM, Koenderink JB, Johnson TN, de Wildt SN, Russel FGM (2020) Physiologically-based pharmacokinetic models for children: starting to reach maturation? Pharmacol Ther 211:107541. https://doi.org/10.1016/j.pharmthera.2020.107541
Volak LP, Hanley MJ, Masse G, Hazarika S, Harmatz JS, Badmaev V, Majeed M, Greenblatt DJ, Court MH (2013) Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 75(2):450–462. https://doi.org/10.1111/j.1365-2125.2012.04364.x
Wang H, Yuan L, Zeng S (2011) Characterizing the effect of UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen. Biochem Pharmacol 82(11):1757–1763. https://doi.org/10.1016/j.bcp.2011.08.004
Wang L, Bao SH, Pan PP, Xia MM, Chen MC, Liang BQ, Dai DP, Cai JP, Hu GX (2015) Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro. Drug Dev Ind Pharm 41(8):1363–1367. https://doi.org/10.3109/03639045.2014.950274
Wechter WJ, Bigornia AE, Murray ED Jr, Levine BH, Young JW (1993) Rac-flurbiprofen is more ulcerogenic than its (S)‐enantiomer. Chirality 5(7):492–494. https://doi.org/10.1002/chir.530050703
Wojtyniak JG, Britz H, Selzer D, Schwab M, Lehr T (2020) Data digitizing: accurate and precise data extraction for quantitative systems pharmacology and physiologically-based pharmacokinetic modeling. CPT Pharmacometrics Syst Pharmacol 9(6):322–331. https://doi.org/10.1002/psp4.12511
Yasar Ü, Tybring G, Hidestrand M, Oscarson M, Ingelman-Sundberg M, Dahl ML, Eliasson E (2001) Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 29(7):1051–1056
Yaşin DS, Yilmaz Ş, Teksin Z (2018) Evaluation of biorelevant media to investigate the dissolution properties on flurbiprofen and to assess cytotoxicity effects on Caco-2 cell line. J Pharm Istanbul Univ 48(3):82–88. https://doi.org/10.26650/IstanbulJPharm.2018.180013
Zhang J, Zhang H, Zhao L, Gu J, Feng Y, An H (2018) Population pharmacokinetic modeling of flurbiprofen, the active metabolite of flurbiprofen axetil, in Chinese patients with postoperative pain. J Pain Res 11:3061–3070. https://doi.org/10.2147/JPR.S176475
Zhuang X, Lu C (2016) PBPK modeling and simulation in drug research and development. Acta Pharm Sin B 6(5):430–440. https://doi.org/10.1016/j.apsb.2016.04.004
Acknowledgements
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT, and Future Planning (Grant No. NRF-2019R1A2C1004582).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no competing interest for this work.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Whang, SS., Cho, C., Jung, E.H. et al. Physiologically based pharmacokinetic (PBPK) modeling of flurbiprofen in different CYP2C9 genotypes. Arch. Pharm. Res. 45, 584–595 (2022). https://doi.org/10.1007/s12272-022-01403-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-022-01403-4